Categories
rss

PAHO: Announcement about Ibuprofen and COVID-19

Murilo Freitas - 12:33, 19 de March de 2020930

Announcement about Ibuprofen and COVID-19 (Washington, DC. 18 March, 2020)

18 Mar 2020

Regarding information that appeared in the media about the risk of using ibuprofen in COVID-19 infections, between March 15 and March 18, 2020 the World Health Organization (WHO) and some regulatory authorities such as the European Medicines Agency (EMA), National Health Services (NHS) in the United Kingdom, Spanish Agency of Medicines and Medical Devices (AEMPS) in Spain, and the Health Products Regulatory (HPRA) in Ireland have stated that there is currently no evidence to support an aggravation of COVID-19 infection with ibuprofen or other NSAIDs.

In short and pending new data, we believe the approach suggested by the UK NHS is appropriate. It addresses the lack of evidence regarding harmful effects of ibuprofen on covid-19 infections and does not advise to discontinue ongoing treatments with this medicine but, if treatment is initiated, prioritizes the use of paracetamol to treat symptoms of the infection.

Download the document 

 
Categories
rss

European Medicine Agency (EMA) gives advice on the use of non-steroidal anti-inflammatories for COVID-19

Murilo Freitas - 14:16, 18 de March de 20201,397

European Medicine Agency (EMA) is aware of reports, especially on social media, which raise questions about whether non-steroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen could worsen coronavirus disease (COVID-19).

There is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID‑19. EMA is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.

For more information go to https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19

 
Categories
Home Posts

World Health Organization (WHO) and COVID-19

Murilo Freitas - 09:54, 17 de March de 20201,429

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV).

Coronavirus disease (COVID-19) is a new strain that was discovered in 2019 and has not been previously identified in humans.

Visit https://www.who.int/health-topics/coronavirus

 
Categories
Home Posts

Uppsala pharmacovigilance program membership: Belize became an associate member of the WHO Program for International Drug Monitoring

Fernanda Lessa - 19:11, 5 de March de 20202,489

Recently, Belize became an associate member of the WHO Program for International Drug Monitoring (WHO PIDM). The WHO PIDM helps countries with pharmacovigilance related activities, including provides software and analytical tools to report and analyze adverse events, provided the country can demonstrate to WHO that it has set up key elements for a successful pharmacovigilance program, including a national center, and can submit a certain number of high quality adverse event reports to WHO.

This accomplishment is the result of a focused effort on the part of the government of Belize and PAHO to strengthen regulatory functions including registration, pharmacovigilance, and post market surveillance. Regulatory strengthening in small countries like Belize can be especially challenging because small countries have fewer people to staff their agencies, small markets that do not incentivize strong industry engagement with regulation, and often times limited financing.

Belize’s strategy to improve its regulatory system makes use of new regional systems available to CARICOM countries, including CARPHA’s Caribbean Regulatory System, and its market surveillance reporting platform, VigiCarib. Belize has become a leader in CARICOM on regulatory strengthening initiatives.

Additional information: https://www.who-umc.org/global-pharmacovigilance/who-programme-for-international-drug-monitoring/

 
PRAIS 2.0